CNTO-5825
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13) . CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis[1].
Product Specifications
UNSPSC
12352203
Target
Interleukin Related
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
[CNTO-5825]
References & Citations
[1]van Hartingsveldt B, et al. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75 (5) :1289-98.
Shipping Conditions
Dry Ice
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Isoform
IL-13
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
036142-ML750 100 µL
GNE, NT (GNE, GLCNE, Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, UDP-GlcNAc-2-epimerase/ManAc kinase, UDP-N-acetylglucosamine 2-epimerase, UDP-GlcNAc-2-epimerase, Uridine diphosphate-N-acetylglucosamine-2-epimerase, N-acetylmannosamine kinase, ManAc kinase) (MaxLight 750) discontinued
Ask
View Details